

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 6

Complete if Known

Application Number	10/010,942
Filing Date	December 6, 2001
First Named Inventor	Guriq Basi, et al.
Art Unit	1649
Examiner Name	Ballard, Kimberly A.
Attorney Docket Number	ELN-002

U.S. PATENT DOCUMENTS

Examiner	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
KAB	679	2005/0255122 A1	11-17-2005	Schenk	
	680	2005/0249727 A1	11-10-2005	Schenk	
	674	6,962,707	11-08-2005	Schenk	
	656	6,946,135	09-20-2005	Schenk	
	657	6,913,745	07-05-2005	Schenk	
	658	6,905,686	06-14-2005	Schenk	
	659	6,890,535	05-10-2005	Schenk	
	661	2005/0009150 A1	01-13-2005	Basi et al.	
	583	2004/0265919 A1	12-30-2004	Vanderstichlele et al.	
	581	2004/0247612 A1	12-09-2004	Wang	
	582	2004/0241164 A1	12-02-2004	Bales et al.	
	673	6,808,712	10-26-2004	Schenk	
	667	6,787,523	09-07-2004	Schenk	
	670	6,787,144	09-07-2004	Schenk	
	668	6,787,143	09-07-2004	Schenk	
	672	6,787,140	09-07-2004	Schenk	
	669	6,787,138	09-07-2004	Schenk	
	671	6,787,129	09-07-2004	Schenk	
	660	2004/0171815 A1	09-02-2004	Schenk et al.	
	675	6,710,226	02-23-2004	Schenk	
	584	5,589,154	12-31-1996	Anderson	
	644	5,618,920	04-08-1997	Robinson et al.	
	643	5,693,762	12-02-1997	Queen et al.	
	642	5,702,906	12-30-1997	Rosenthal	
✓	646	4,816,567	03-28-1989	Cabilly et al.	
	645	5,258,498	11-02-1993	Huston et al.	
KAB	647	4,816,397	03-28-1989	Boss et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD- YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
KAB	587	JP	7-165799	A	06-27-1995			abst. only

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60284284 v1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2

of

6

Complete if Known

Application Number	10/010,942
Filing Date	December 6, 2001
First Named Inventor	Guriq Basi, et al.
Art Unit	1649
Examiner Name	Ballard, Kimberly A.
Attorney Docket Number	ELN-002

KAB	632	JP	7-132033	A	05-23-1995		abst. only
	631	JP	62-267297	A	11-19-1987		abst. only
	585	WO	04/080419	A2	09-23-2004		
	586	WO	03/077858	A2, A3	09-25-2003		
	633	WO	96/08565	A2	03-21-1996		
	630	WO	95/17085	A1	06-29-1995		
KAB	648	WO	91/09967	A1	07-11-1991		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
KAB	663	ALBERTS et al., eds. <i>Molecular Biology of The Cell, Third Edition</i> , chapter 23, pages 1208-1209 (1994).	
	649	AMIT et al., "Three-Dimensional Structure of an Antigen-Antibody Complex at 2.8 Å Resolution," <i>Science</i> , 233:747-753 (1986).	
	588	ANDERSON, J. P., "Exact cleavage site of Alzheimer amyloid precursor in neuronal PC 12 cells," <i>Neuroscience Letters</i>, 128(1):126-128 (1991).	*
	589	ANDERSON, M. W., "Amending the amyloid hypothesis," <i>The Scientist</i>, 18(20):28-29 (2004).	*
	677	ANKARCORONA et al., "Biomarkers for apoptosis in Alzheimer's disease," <i>Int. J. Geriatric Psychiatry</i> , 20:101-105 (2005).	
	590	BACSKAI et al., "Non-Fc-mediated mechanisms are involved in clearance of amyloid-β in vivo by immunotherapy," <i>J. Neurosci.</i> , 22(18):7873-7878 (2002).	
	639	Chimicon International, "Mouse Anti-Amyloid Beta Protein Monoclonal Antibody," Catalog # MAB1561	
	501	CHROMY et al., "Self assembly of Aβ(1-42) into globular neurotoxins," <i>Biochemistry</i>, 42(44):13740-13760 (2003).	*
	592	CITRON et al., "Evidence that the 42- and 40- amino acid forms of amyloid-β protein are generated from the β-amyloid precursor protein by different protease activities," <i>PNAS</i>, 93(23):13170-13175 (1996).	*
	603	CITRON, M., "Alzheimer's disease: treatments in discovery and development," <i>Nat. Neurosci.</i>, 5:1055-1057 (2002).	*
KAB	594	DEMATOS et al., "Brain to plasma amyloid β efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease," <i>Science</i>, 295(5563):2264-2267 (2002).	*

Examiner
Signature

Date
Considered

*Duplic-
ates.
Do not
Print.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60284284 v1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	10/010,942
	Filing Date	December 6, 2001
	First Named Inventor	Guriq Basi, et al.
	Art Unit	1649
	Examiner Name	Ballard, Kimberly A.
Sheet 3 of 6	Attorney Docket Number	ELN-002

KAB	595	DODART et al., "Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model," <u>Nat. Neurosci.</u> , 5(5):452-457 (2002).	*
	596	DODART et al., "Immunotherapy for Alzheimer's disease," <u>Lancet Neurol.</u>, 2(4):215-220 (2003).	*
	597	DOVEY et al., "Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain," <u>J. Neurochem.</u> , 76(1):173-181 (2001).	*
	598	DIFFE et al., "Increased amyloid-β42/43 in brains of mice expressing mutant presenilin 1," <u>Nature</u> 383(6602):710-713 (1996).	*
	599	ERIKSEN et al., "NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo," <u>J. Clin. Invest.</u> , 112(3):440-449 (2003).	*
	600	EINDEIS, M. A., "Approaches to discovery and characterization of inhibitors of amyloid β-peptide polymerization," <u>Biochem. Biophys. Acta</u> , 1502(1):76-84 (2000).	*
	650	FOOTE et al., "Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops," <u>J. Mol. Biol.</u> , 224:487-499 (1992).	
	601	FRENKEL et al., "Reduction of β-amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization," <u>Vaccine</u> , 21(11-12):1060-1065 (2003).	*
	602	FRENKEL et al., "Towards Alzheimer's β-amyloid vaccination," <u>Biologicals</u> , 23(3-4):243-247 (2001).	*
	603	GELINAS et al., "Immunotherapy for Alzheimer's disease," <u>PNAS</u> , 101(suppl. 2):14657-14662 (2004).	*
	604	GONG et al., "Alzheimer's disease affected brain: presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss," <u>PNAS</u> , 100(18):10417-10422 (2003).	*
	605	GREENBERG et al., "Alzheimer disease's double-edged vaccine," <u>Nat. Med.</u> , 3(4):399-399 (2003).	*
	606	HAAGB, O., "New hope for Alzheimer disease vaccine," <u>Nat. Med.</u> , 8(11):1195-1196 (2002).	*
	664	HARLOW et al., eds., <i>Antibodies: A Laboratory Manual</i> , pages 71-82 (1998).	
↓	607	HOCK et al., "Generation of antibodies specific for β-amyloid by vaccination of patients with Alzheimer disease," <u>Nat. Med.</u> , 8(11):1270-1275 (2002).	*
KAB	662	IDA et al., "Analysis of Heterogeneous βA4 Peptides in Human Cerebrospinal Fluid and Blood by a Newly Developed Sensitive Western Blot Assay," <u>J. Biol. Chem.</u> , 271(37):22908-22914 (1996).	

*Duplicates

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Do not
print.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60284284 v1



PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/010,942
		Filing Date	December 6, 2001
		First Named Inventor	Guriq Basi, et al.
		Art Unit	1649
		Examiner Name	Ballard, Kimberly A.
Sheet	4	of	6
		Attorney Docket Number	ELN-002

KAB	600	IRIZARRY et al., "Alzheimer disease therapeutics," J. Neuropathol. Exp. Neurol., 60(10):923-928 (2001).	*
	600	JANUS et al., "Transgenic mouse models of Alzheimer's Disease," Physiol. Behav., 73(5):873-886 (2001).	*
	640	JUNG et al., "Alzheimer's Beta-amyloid Precursor Protein Is Expressed on the Surface of Immediately Ex Vivo Brain Cells: a Flow Cytometric Study," J. Neurosci. Res., 46:336-348 (1996).	
	628	KOFLER et al. "Mechanism of allergic cross-reactions-III. cDNA cloning and variable-region sequence analysis of two IgE antibodies specific for trinitrophenyl." Mol Immunol, 29(2):161-6 (1992).	
	635	KOFLER et al. "IgE antibody light chain (VJ) [Mus musculus]." GenBank Accession No. CAA46659. Retrieved from the internet at http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&val=1870480 on August 26, 2005.	
	636	KOFLER et al. "M.musculus DNA for IgE antibody light chain (VJ)." GenBank Accession No. X65775. Retrieved from the internet at http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=312078 on August 26, 2005.	
	627	KRISHNAN et al., "Correlation between the amino acid position of arginine in VH-CDR3 and specificity for native DNA among autoimmune antibodies." J Immunol. 157(6):2430-9 (1996).	
	634	KRISHNAN et al. "anti-DNA immunoglobulin light chain IgG [Mus musculus]." Genbank Accession No. AAB488000. Retrieved from the internet at http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&val=1870480 on 08-26-2005.	
	651	LANDOLFI et al., "The Integrity of the Ball-and Socket Joint Between V and C Domains Is Essential for Complete Activity of a Humanized Antibody," J. Immunology, pages 1748-1754 (2001).	
	665	LO et al., "High level expression and secretion of Fc-X fusion proteins in mammalian cells," Protein Engineering, 11(6):495-500 (1998).	
	666	MANDEL et al., "Clinical trials in neurological disorders using AAV vectors: promises and challenges," Curr. Opin. Mol. Ther., 6(5):482-490 (2004).	
	610	MATTOON et al., "Good and bad amyloid antibodies," Science, 301(5641):1645-1649 (2003).	*
	611	MCLAURIN et al., "Therapeutically effective antibodies against amyloid- B peptide target amyloid- B residues and 4-10 and inhibit cytotoxicity and fibrillogenesis," Nat Med., 8(11):1263-1269 (2002).	*
	612	MONSONEGO et al., "Increased T cell reactivity to amyloid B protein in older humans and patients with Alzheimer's disease," J. Clin. Invest., 112(3):415-422 (2003).	*
KAB	613	MONSONEGO et al., "Immunotherapeutic approaches to Alzheimer's disease," Science, 302(5646):834-838 (2003).	*


Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60284284 v1

*Duplicates
Do not
print.



Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/010,942
		Filing Date	December 6, 2001
		First Named Inventor	Guriq Basi, et al.
		Art Unit	1649
		Examiner Name	Ballard, Kimberly A.
Sheet 5 of 6	Attorney Docket Number	ELN-002	

KAB	652	ORLANDI et al., "Cloning immunoglobulin variable domains for expression by the polymerase chain reaction," <u>PNAS</u> , 86:3833-3837 (1989).	
	614	PAGANETTI et al. "Amyloid precursor protein truncated at any of the v-secretase sites is not cleaved to β -amyloid," <u>J. Neurosci. Res.</u> , 46(3):283-293 (1996).	*
	615	PALLITTO et al. "Recognition sequence design for peptidyl modulators of β -amyloid aggregation and toxicity," <u>Biochemistry</u> , 38(12):3570-3578 (1999).	*
	654	PANKA et al., "Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies," <u>PNAS</u> , 85:3080-3084 (1998).	
	653	PAUL, W. E., eds., <i>Fundamental Immunology</i> , Third Edition, pages 292-295, Raven Press, New York (1993).	
	616	PEEIFFER et al. "Cerebral hemorrhage after passive anti-A β immunotherapy." <u>Science</u> 298(5597):1379 (2002).	*
	641	RACKE et al., "Exacerbation of Cerebral Amyloid Angiopathy-Associated Microhemorrhage in Amyloid Precursor Protein Transgenic Mice by Immunotherapy Is Dependent on Antibody Recognition of Deposited Forms of amyloid β ," <u>J. Neurosci.</u> , 25(3):629-636 (2005).	
	638	Research Corporation Technology News, "THP and SangStat Partner to Develop Humanized Polyclonal Antibody Drugs," 11/11/02.	
	626	"Researchers Develop Blood Test to Diagnose Alzheimer's- Type Changes in Mice," downloaded from www.businesswire.com on 12/15/04.	
	655	RUDIHOFF et al., "Single amino acid substitution altering antigen-binding specificity," <u>PNAS</u> , 79:1979-1983 (1982).	
	647	SCHMID, R. E., "Study suggest Alzheimer vaccine fix," from www.msnbc.com/news, pages 1-5 (2002).	*
	629	SEIDL, K.J. et al. "Predominant VH genes expressed in innate antibodies are associated with distinctive antigen-binding sites." <u>Proc Natl Acad Sci U S A</u> . 96(5):2262-7 (1999).	
	637	SEIDL, K.J. et al. "immunoglobulin heavy chain VH3609-JH3 region [Mus musculus]." GenBank Accession No. AAD26773. Retrieved from the internet at http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&val=4633434 on August 26, 2005.	
✓	610	SELKOE, D. J., "Alzheimer's disease is a synaptic failure," <u>Science</u> , 298(5584):788-791 (2002).	*
KAB	622	SERGEANT et al. "Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach," <u>J. Neurochem.</u> , 85(6):1581-1591 (2003).	*


*Duplicates - Do not print.

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60284284 v1



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 6

of 6

Complete if Known

Application Number	10/010,942
Filing Date	December 6, 2001
First Named Inventor	Guriq Basi, et al.
Art Unit	1649
Examiner Name	Ballard, Kimberly A.
Attorney Docket Number	ELN-002

KAB	619	SIGURDSSON et al., "Immunization with a nontoxic/nonfibrillar amyloid- β homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice," <u>Am. J. Pathol.</u> , 159(2):433-447 (2001).	*
	620	SOLOMON, B., "Generation and brain delivery of anti-aggregating antibodies against β -amyloid plaques using phage display technology," <u>J. Neural Transm. Suppl.</u> , 62:321-325 (2002).	*
	621	SOLOMON, B., "Immunotherapeutic strategies for prevention and treatment of Alzheimer's disease," <u>DNA and Cell Biology</u> , 20(11):697-703 (2001).	*
	678	SOUDER et al., "Overview of Alzheimer's disease," <u>Nurs. Clin. N. Am.</u> , 39:545-559 (2004).	
	623	WALSH et al., "Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo," <u>Nature</u> , 416(6880):535-539 (2002).	
	624	WASHINGTON UNIVERSITY IN ST. LOUIS SCHOOL OF MEDICINE, "Study gives Clues to Working of Anti-Alzheimer Antibody," downloaded from www.medicine.wustl.edu/~wumpa/news on 12/15/04.	*
✓	676	Webster's New World Dictionary, page 1387, therapeutic (1988).	
KAB	625	WHITE et al., "Immunotherapy as a therapeutic treatment for neurodegenerative disorders," <u>J. Neurochem.</u> , 87(4):801-808 (2003).	*

*Duplicates - Do not print.

Examiner Signature	/Kimberly Ballard/	Date Considered	05/09/2006
--------------------	--------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60284284 v1



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete If Known		
			Application Number	10/010942-Conf. #5594	
			Filing Date	December 6, 2001	
			First Named Inventor	Guriq BASI	
			Art Unit	1649	
			Examiner Name	K. A. Ballard	
Sheet	1	of	1	Attorney Docket Number	ELN-002

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
KAB	686	US-6,972,127-A1	12-06-2005	Schenk	
	693	US-20050191314-A1	09-01-2005	Schenk	
	685	US-20050163788-A1	07-28-2005	Schenk	
	683	US-20050059802-A1	03-17-2005	Schenk et al.	
KAB	684	US-20050059591-A1	03-17-2005	Schenk et al.	

U.S. PATENT APPLICATIONS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			
KAB	691	11/245,524	10-07-2005	Schenk		
KAB	692	11,245,916	10-07-2005	Schenk		

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ CITE NO.: Those application(s) which are marked with an single asterisk () next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ² Applicant's unique citation designation number (optional). ³ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
KAB ↓ ↓	681	AULD et al., "Alzheimer's disease and the basal forebrain cholinergic system: relations to β -amyloid peptides, cognition, and treatment strategies," <u>Progress in Neurobiol.</u> , 68:209-245 (2002)			
	687	COX et al., "Adjuvants - a classification and review of their modes of action," <u>Vaccine</u> , 15(3):248-256 (1997)			
	689	DE LUSTIG et al., "Peripheral Markers and Diagnostic Criteria in Alzheimer's Disease: Critical Evaluations," <u>Rev. in Neurosciences</u> , 5:213-225 (1994)			
	694	GUPTA et al., "Adjuvants for human vaccines - current status, problems, and future prospects," <u>Vaccine</u> , 13(14):1263-1275 (1995)			
	682	PARNETTI et al., "Cognitive Enhancement Therapy for Alzheimer's Disease, The Way Forward," <u>Drugs</u> , 53(5):752-768 (1997)			
	690	VICKERS, J.C., "A Vaccine Against Alzheimer's Disease," <u>Drugs Aging</u> , 19(7):487-494 (2002)			
KAB	688	Webster's New World Dictionary of American English, Third College Edition, page 1078 (1988)			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Kimberly Ballard/	Date Considered	05/09/2006
-----------------------	--------------------	--------------------	------------



PTO/SB/08a/b (07-05)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/010942-Conf. #5594
				Filing Date	December 6, 2001
				First Named Inventor	Guriq BASI
				Art Unit	1649
				Examiner Name	K. A. Ballard
Sheet	1	of	2	Attorney Docket Number	ELN-002

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
KAB	702*	US-6,548,640	04-15-2003	Winter	
	703*	US-5,225,539	07-06-1993	Winter	
	704*	US-6,180,370	01-30-2001	Queen et al.	
	705*	US-5,693,761	12-02-1997	Queen et al.	
	706*	US-5,585,089	12-17-1996	Queen et al.	
	707*	US-5,859,205	01-12-1999	Adair et al.	
	708*	US-20030039645-A1	10-14-2003	Adair et al.	
	709*	US-6,632,927-A1	10-14-2003	Adair et al.	
	710*	US-6,407,213	06-18-2002	Carter et al.	
	711*	US-6,054,297	04-25-2000	Carter et al.	
	712*	US-6,639,055	10-28-2003	Carter et al.	
	713*	US-6,936,698-A1	08-30-2005	Taylor	
	714*	US-20050123534-A1	06-09-2005	Adair et al.	
	715*	US-20050136054-A1	06-23-2005	Adair et al.	
	716*	US-6,933,368-A1	08-23-2005	Co et al.	
	717*	US-5,648,260	07-15-1997	Winter et al.	
	718*	US-5,624,821	04-29-1997	Winter et al.	
	719*	US-6,165,745	12-26-2000	Ward et al.	
	720*	US-6,277,375	08-21-2001	Ward	
	721*	US-5,677,425	10-14-1997	Bodmer et al.	
	722*	US-5,869,046	02-09-1999	Presta et al.	
	723*	US-6,121,022	09-19-2000	Presta et al.	
	724*	US-6,194,551	02-27-2001	Idusogie et al.	
	725*	US-6,538,124	03-25-2003	Idusogie et al.	
KAB	726*	US-6,528,624	03-04-2003	Idusogie et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			
KAB	701	WO-2005/014041-A2	02-17-2005	Novartis Pharma GmbH		
KAB	696	WO-95/06407-A1	03-09-1995	The Regents of the University of California et al		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/010942-Conf. #5594
				Filing Date	December 6, 2001
				First Named Inventor	Guriq BASI
				Art Unit	1649
				Examiner Name	K. A. Ballard
Sheet	2	of	2	Attorney Docket Number	ELN-002

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
KAB	699	Clayton, David F. et al, "Synucleins in Synaptic Plasticity and Neurodegenerative Disorders," <i>Journal of Neuroscience Research</i> , Vol. 58:120-129 (1999)		
	698	Dictionary.com definition of, "prophylactic," pages 1-3 downloaded from internet 10/12/05		
	695	Kuo, Yu-Min et al, "Water-soluble A β (N-40, N-42) Oligomers in Normal and Alzheimer Disease Brains," <i>The Journal of Biological Chemistry</i> , Vol. 271(8):4077-4081 (1996)		
	697	Small, Gary W. et al, "Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease," <i>PNAS</i> , Vol. 97(11):6037-6042 (2000)		
KAB	700	Valleix, Sophie et al, "Hereditary renal amyloidosis caused by a new variant lysozyme W64R in a French Family," <i>Kidney International</i> , Vol. 61:907-912 (2002)		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Kimberly Ballard/	Date Considered	05/09/2006
-----------------------	--------------------	--------------------	------------



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	10/010,942
				Filing Date	December 6, 2001
				First Named Inventor	Guriq Basi
				Art Unit	1647
				Examiner Name	Christopher J. Nichols
Sheet	1	of	3	Attorney Docket Number	ELN-002

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	†
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
CJN	548	Anderson, J.P., et al. Exact cleavage site of Alzheimer amyloid precursor in neuronal PC-12 cells." <i>Neurosci Lett.</i> 1991 Jul 8; 128(1):126-8.			
	549	Anderson, M.W. "Amending the amyloid hypothesis." <i>The Scientist.</i> 2004 Oct 25; 18(20).			
	550	Bacskaï, B.J., et al. "Imaging of amyloid- β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy." <i>Nat Med.</i> 2001 Mar; 7(3):369-72.			
	551	Bacskaï, B.J., et al. "Non-Fc-mediated mechanisms are involved in clearance of amyloid- β in vivo by immunotherapy." <i>J Neurosci.</i> 2002 Sep 15; 22(18):7873-8.			
	552	Check, E. "Battle of the mind." <i>Nature.</i> 2003 Mar 27; 422(6930):370-2.			
	553	Chromy, B.A., et al. "Self-assembly of A β (1-42) into globular neurotoxins." <i>Biochemistry.</i> 2003 Nov 11; 42(44):12749-60.			
	554	Citron, M., et al. "Evidence that the 42- and 40-amino acid forms of amyloid- β protein are generated from the β -amyloid precursor protein by different protease activities." <i>Proc Natl Acad Sci USA.</i> 1996 Nov 12; 93(23):13170-5.			
	555	Citron, M. "Alzheimer's disease: treatments in discovery and development." <i>Nat Neurosci.</i> 2002 Nov; 5:1055-7.			
	556	DeMattos, R.B., et al. "Brain to plasma amyloid- β efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease." <i>Science.</i> 2002 Mar 22; 295(5563):2264-7.			
	557	DeMattos, R.B., et al. "Peripheral anti-A β antibody alters CNS and plasma A β clearance and decreases brain A β burden in a mouse model of Alzheimer's disease." <i>Proc Natl Acad Sci USA.</i> 2001 Jul 17; 98(15):8850-5.			
558	Dodart, J-C., et al. "Immunization reverses memory deficits without reducing brain A β burden in Alzheimer's disease model." <i>Nat Neurosci.</i> 2002 May; 5(5):452-7.				

Duplicate
Do not print.
KAB 5/10/06

Examiner Signature		Date Considered	11/18/05
-----------------------	--	--------------------	----------



PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/010,942		
		Filing Date	December 6, 2001		
		First Named Inventor	Guriq Basi		
		Art Unit	1647		
		Examiner Name	Christopher J. Nichols		
Sheet	3	of	3	Attorney Docket Number	ELN-002

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
592	578	Paganetti, P.A., et al. "Amyloid precursor protein truncated at any of the γ -secretase sites is not cleaved to β -amyloid." <i>J Neurosci Res.</i> 1996 Nov 1; 46(3):283-93.	
	579	Pallitto, M.M., et al. "Recognition sequence design for peptidyl modulators of β -amyloid aggregation and toxicity." <i>Biochemistry.</i> 1999 Mar 23; 38(12):3570-8.	
	580	Pfeifer, M., et al. "Cerebral hemorrhage after passive anti-A β immunotherapy." <i>Science.</i> 2002 Nov 15; 298(5597):1379.	
	581	Schmid, R.E. "Study suggests Alzheimer vaccine fix." www.msnbc.com/news . 2002; 1-5.	
	582	Selkoe, D.J. "Alzheimer's disease is a synaptic failure." <i>Science.</i> 2002 Oct 25; 298(5594):789-91.	
	583	Sigurdsson, E.M., et al. "Immunization with a nontoxic/nonfibrillar amyloid- β homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice." <i>Am J Pathol.</i> 2001 Aug; 159(2):439-47.	
	584	Solomon, B., et al. "Generation and brain delivery of anti-aggregating antibodies against β -amyloid plaques using phage display technology." <i>J Neural Transm Suppl.</i> 2002; (62):321-5.	
	585	Solomon, B. "Immunotherapeutic strategies for prevention and treatment of Alzheimer's disease." <i>DNA Cell Biol.</i> 2001 Nov; 20(11):697-703.	
	586	White, A.R., et al. "Immunotherapy as a therapeutic treatment for neurodegenerative disorders." <i>J Neurochem.</i> 2003 Nov; 87(4):801-8.	
	587	Nicoll, J.A. et al. "Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report." <i>Nat Med.</i> 2003 Apr; 9(4):448-52.	
	588	Pan, W., et al. "Antibodies to β -amyloid decrease the blood-to-brain transfer of β -amyloid peptide." <i>Exp Biol Med (Maywood).</i> 2002 Sep; 227(8):809-15.	
	589	Sergeant, N., et al. "Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach." <i>J Neurochem.</i> 2003 Jun; 85(6):1581-91.	
	590	Walsh, D.M., et al. "Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo." <i>Nature.</i> 2002 Apr 4; 416(6880):535-9.	
	591	Washington University in St. Louis School of Medicine. "Study Gives Clues to Working of Anti-Alzheimer Antibody." Retrieved from internet www.medicine.wustl.edu/~wumpu/news , December 15, 2004.	
592	592	"Researchers Develop Blood Test to Diagnose Alzheimer's-Type Changes in Mice." Retrieved from internet www.businesswire.com , December 15, 2004.	

Duplicate.
Do not
print.
5/10/06
KAB

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
²Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	11/18/05
--------------------	--	-----------------	----------



DISSENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
KAB	✓B1	JP 7-165799	06/95	Japan			Abstract Only	
	✓B2	WO 00/23082 A1	04/00	WO				
	✓B3	WO 00/72000 A2, A3	05/00	WO				
	✓B4	WO 02/088306 A2	11/02	WO				
KAB	✓B5	WO 02/088307 A2	11/02	WO				

[illegible]

Examiner	/Kimberly Ballard/	Date Considered	05/09/2006
*EXAMINER:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

*Duplicates -Do not print.

5/10/06 KAR